Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
1
Neutral
6
Bullish
7
Bearish
3
Neutral
6
Bullish
37
Bearish
2
Neutral
0
Bullish
30
Discovery themes featuring this stock| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
220.20 | 910 Cr | 6.69 | 5.47 | 0.18 | 13.86 | 16.04 | 12.18 | |
607.40 | 716 Cr | 9.31 | 2.80 | 0.12 | 10.92 | 16.89 | 7.42 | |
141.05 | 282 Cr | 17.06 | 3.26 | 0.00 | 19.49 | 16.44 | 12.65 | |
33.80 | 257 Cr | 31.87 | 2.24 | 0.00 | 14.14 | 16.25 | 21.76 | |
26.35 | 58 Cr | 12.10 | 0.61 | 0.00 | 4.22 | 7.95 | 2.74 | |
0.61 | 24 Cr | — | 0.38 | 0.00 | 0.26 | 0.26 | -0.45 | |
2.59 | 19 Cr | -10.36 | 2.11 | 0.00 | -17.64 | -3.52 | -1.32 |
Titan Biotech Ltd. specializes in manufacturing biological peptones, extracts, and dehydrated culture media to support the growth of microorganisms crucial for diagnostics, vaccines, and pharmaceuticals.
The company uses animal and vegetable components to convert them into peptones, which become core sources for culture media, utilized broadly in healthcare and microbiological research.
Historically, Titan Biotech has expanded its product line to include gamma-irradiated culture media, lab chemicals, and agaroses, which serve research institutes and commercial applications.
In 2009-10, Titan Biotech developed Amino acid Chelates and harmonized media, marking significant strides in enhancing its product offerings.
The company contributes meaningfully to pharmaceutical and microbiology industries by supplying key materials for microbial growth and testing requirements.
Pharmaceuticals
Biotechnology
910 Cr
Low Risk
7.7
66.6
—
5.5
312.40
74.73
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Titan Biotech Ltd (TITANBIO) is currently trading at 253.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Titan Biotech Ltd. specializes in manufacturing biological peptones, extracts, and dehydrated culture media to support the growth of microorganisms crucial for diagnostics, vaccines, and pharmaceuticals. The company uses animal and vegetable components to convert them into peptones, which become core sources for culture media, utilized broadly in healthcare and microbiological research. Historically, Titan Biotech has expanded its product line to include gamma-irradiated culture media, lab chemicals, and agaroses, which serve research institutes and commercial applications. In 2009-10, Titan Biotech developed Amino acid Chelates and harmonized media, marking significant strides in enhancing its product offerings. The company contributes meaningfully to pharmaceutical and microbiology industries by supplying key materials for microbial growth and testing requirements.
Over the past 52 weeks, Titan Biotech Ltd has traded between a low of ₹74.73 and a high of ₹312.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Titan Biotech Ltd has a market capitalization of approximately 909.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Titan Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 7.71 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 909.83 Cr, Titan Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Titan Biotech Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Titan Biotech Ltd is 7.71. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Stock Split
Titan Biotech sub-divided each Rs.10 equity share into five Rs.2 shares; new ISIN INE150C01029 has been credited in NSDL/CDSL (effective 21-Feb-2026); depositories' confirmations dated 23 & 27 Feb 2026.
Stock Split
Titan Biotech notified that each equity share of Rs.10 was sub-divided into 5 equity shares of Rs.2 each and the sub-divided shares have been credited under new ISIN INE150C01029 by NSDL and CDSL (effective Feb 21, 2026).
